Datavault AI Inc. (NASDAQ: DVLT) has announced an exclusive patent license agreement with Wellgistics Health Inc., targeting inefficiencies in prescription drug pricing driven by pharmacy benefit managers (PBMs). The agreement grants Wellgistics sole access within its market segment to Datavault AI’s proprietary technologies, including the PharmacyChain platform, which tracks prescription fulfillment from manufacturer to patient and automates processes traditionally handled by PBMs.
Prescription drug prices in the United States remain among the highest globally, partly due to complex rebate structures controlled by PBMs. These intermediaries negotiate discounts with drug manufacturers but often lack transparency, leading to higher costs for consumers and employers. Datavault AI’s technology aims to streamline this process by providing a transparent, automated system that reduces reliance on traditional intermediaries.
Under the agreement, Wellgistics Health will integrate Datavault AI’s intellectual property into its operations, with exclusivity designed to create stronger commercial incentives for adoption. This arrangement also reinforces the value of Datavault AI’s patent portfolio, which focuses on AI-driven data monetization and digital asset infrastructure. By granting exclusive rights, Datavault AI positions its technology as a key solution for addressing systemic inefficiencies in the healthcare supply chain.
The PharmacyChain platform is central to this initiative, offering end-to-end visibility and automation for prescription fulfillment. This could potentially lower costs for patients and payers by eliminating unnecessary steps and fees associated with PBMs. The move comes as regulators and lawmakers increasingly scrutinize PBM practices, with calls for greater transparency and reform.
For Datavault AI, this agreement marks a strategic entry into the healthcare sector, leveraging its expertise in data monetization and AI. The company’s technology is designed to track and manage pharmaceutical transactions, providing real-time data that can be used to optimize pricing and reduce waste. Wellgistics Health, a healthcare logistics and technology company, will deploy the platform across its network, aiming to improve efficiency and cost-effectiveness.
Investors and industry observers are closely watching this development, as it could signal a shift toward more technology-driven solutions in the pharmaceutical supply chain. If successful, the platform could set a precedent for other companies seeking to bypass traditional PBM structures. For more information on Datavault AI, visit the company’s newsroom at https://ibn.fm/DVLT.
This announcement highlights the growing role of AI and data analytics in addressing long-standing issues in healthcare pricing. By automating and streamlining processes, companies like Datavault AI are challenging established intermediaries and offering new pathways for cost reduction. The exclusive nature of the license underscores the value of proprietary technology in creating competitive advantages within niche markets.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Datavault AI Licenses Technology to Wellgistics Health to Combat PBM-Driven Drug Pricing Inefficiencies.